Review Article

Pharmacovigilance and Adverse Drug Reactions: A Comprehensive Review for Safer Use of Medicines

Manoj B. Kadam[1], **Atul Jadhav**[1], **Rachana Patil**[1]
[1]*Department of Dravyaguna, Dr. G. D. Pol Foundation Y. M. T. Ayurvedic Medical College, Kharghar.*

Corresponding Author:
Manoj B. Kadam
E-mail: drmanoj.kadam@gmail.com

Submission: 17.11.2025 Acceptance: 02.12.2025 Publication: 29.12.2025

Abstract-

Pharmacovigilance plays a pivotal role in modern healthcare by ensuring the safety of medicines throughout their life cycle. Adverse drug reactions (ADRs) remain a significant cause of morbidity, mortality, and increased healthcare expenditure worldwide. Despite rigorous pre-marketing clinical trials, many drug-related risks become evident only after widespread clinical use. This review critically examines the concept, scope, and operational aspects of pharmacovigilance, with emphasis on adverse drug reactions, their classification, detection methods, reporting systems, and contemporary challenges. Novel, context-specific illustrations are presented to highlight real-world complexities in ADR identification. Strengthening pharmacovigilance systems through improved reporting, education, and regulatory coordination is essential for promoting patient safety and rational pharmacotherapy.

Keywords: Pharmacovigilance, Adverse Drug Reaction, Drug Safety, Post-Marketing Surveillance, Risk Management

Introduction-

Medicines are fundamental to disease prevention and treatment, yet no drug is entirely free from risk. Adverse drug reactions remain an under-recognized but critical public health problem, contributing to prolonged hospital stays, therapy discontinuation, and avoidable complications[2,3]. While clinical trials provide essential data on drug efficacy and safety, their controlled conditions, limited sample sizes, and short duration restrict the detection of rare, delayed, or population-specific adverse effects[2].

Pharmacovigilance has therefore emerged as a dynamic discipline dedicated to identifying, evaluating, and preventing drug-related harm in real-world clinical settings[1]. In an era of expanding therapeutic options, biologics, fixed-dose combinations, and self-medication practices, pharmacovigilance has become indispensable for ensuring patient safety[4].

Concept and Scope of Pharmacovigilance-

The World Health Organization defines pharmacovigilance as the science and activities concerned with the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems[1].

The scope of pharmacovigilance includes:

- Adverse drug reactions
- Medication errors
- Drug–drug and drug–food interactions
- Lack of therapeutic efficacy
- Drug misuse and abuse
- Safety of vaccines and biologics[1]

Pharmacovigilance operates continuously, extending beyond drug approval into post-marketing phases where exposure to diverse populations reveals previously unrecognized risks[4].

Adverse Drug Reactions: Definition and Classification-

An adverse drug reaction is a harmful and unintended response to a medicine occurring at doses normally used for prevention, diagnosis, or treatment of disease[2].

Classification of ADRs-

ADRs may be categorized using multiple approaches[2,5] :

- Dose-related reactions – predictable and related to pharmacological action
- Non–dose-related reactions – unpredictable and often immune-mediated
- Time-related reactions – occurring after prolonged or delayed exposure
- Withdrawal reactions – appearing after sudden discontinuation
- Therapeutic failure – absence of expected clinical response

This multifaceted classification aids clinicians in identifying causality and implementing preventive strategies[2].

Table 1- Classification of Adverse Drug Reactions:

Basis of Classification	Category	Description	Illustrative Description
Predictability	Type A (Augmented)	Dose-dependent, predictable from known pharmacology	Excessive pharmacological response at therapeutic dose
	Type B (Bizarre)	Non–dose-dependent, unpredictable	Occurs independent of drug's primary action
Time relationship	Acute	Occurs shortly after drug administration	Immediate onset following exposure
	Subacute	Appears after repeated dosing	Develops over days or weeks
	Delayed	Occurs long after exposure	Manifests months after therapy
Severity	Mild	No intervention required	Self-limiting symptoms
	Moderate	Requires dose modification or treatment	Interferes with daily activity
	Severe	Life-threatening or fatal	Requires hospitalization
Outcome	Reversible	Resolves after discontinuation	Complete recovery observed
	Irreversible	Persistent damage	Long-term functional impairment

Mechanisms Underlying Adverse Drug Reactions-

ADRs may result from:

- Altered pharmacokinetics due to age, organ dysfunction, or genetic variability
- Pharmacodynamic sensitivity or exaggerated receptor responses
- Drug interactions altering metabolism or clearance
- Off-target effects not identified during early development[3]

Understanding these mechanisms is essential for anticipating risk and individualizing therapy[5].

Table 2- Common Factors Predisposing to Adverse Drug Reactions:

Factor Category	Examples
Patient-related	Advanced age, pediatric population, pregnancy
Disease-related	Renal or hepatic impairment, chronic illness
Drug-related	Narrow therapeutic index, long half-life
Therapy-related	Polypharmacy, prolonged treatment duration
Behavioral factors	Self-medication, non-adherence
System-related	Inadequate monitoring, poor follow-up

Illustration 1: Delayed Recognition of ADR-

A patient receiving long-term acid-suppressive therapy for gastrointestinal symptoms presents with unexplained muscle cramps and fatigue after several months. Laboratory evaluation reveals electrolyte imbalance. The adverse reaction remained unnoticed due to its gradual onset and nonspecific symptoms, emphasizing the importance of long-term pharmacovigilance beyond acute reactions[3,6].

Illustration 2: ADR Masked by Disease Progression-

A patient undergoing treatment for chronic inflammatory disease develops subtle cognitive changes. These changes are initially attributed to disease progression but later linked to cumulative drug exposure. This scenario illustrates how ADRs may be overlooked when clinical manifestations overlap with underlying disease features[4].

These examples underscore the need for vigilance even when reactions are atypical or delayed.

Detection and Assessment of ADRs-

Pharmacovigilance relies on multiple methods for ADR detection[6]:

- Spontaneous reporting systems – cornerstone of post-marketing surveillance
- Cohort and case–control studies – for risk quantification
- Signal detection techniques – identifying patterns suggesting potential risks
- Risk–benefit assessment – continuous evaluation of therapeutic value

Causality assessment tools such as the WHO–UMC system and the Naranjo algorithm support systematic evaluation of suspected ADRs[5].

Table 3- Comparison of ADR Detection Methods:

Method	Strengths	Limitations
Spontaneous reporting	Simple, cost-effective	Underreporting, reporting bias
Cohort studies	Risk estimation	Time-consuming, expensive
Case–control studies	Useful for rare ADRs	Recall bias
Electronic health records	Large real-world data	Data quality variability
Active surveillance	Early detection	Resource intensive

Pharmacovigilance Systems and Reporting-

National and international pharmacovigilance programs coordinate the collection and analysis of ADR data[1,4]. Healthcare professionals play a central role in reporting suspected reactions, even when causality is uncertain[7].

Underreporting remains a major limitation, often due to lack of awareness, time constraints or the misconception that only severe reactions require reporting[8].

Pharmacovigilance Reporting Workflow:

Patient Experiences Suspected ADR
↓
Healthcare Professional Identifies Event
↓
Initial Clinical Assessment
(severity, time relationship, drug history)
↓
Documentation of ADR
(drug, dose, duration, outcome)
↓
Submission to National Pharmacovigilance System
↓
Signal Detection and Data Analysis
↓
Regulatory Review and Risk Assessment
↓
Risk Minimization Measures
(label change / alerts / restrictions)

Contemporary Challenges in Pharmacovigilance-

Despite advancements, several challenges persist[4,7].

- Increasing polypharmacy and aging populations
- Introduction of complex biologics and gene-based therapies
- Self-medication and over-the-counter drug misuse
- Inconsistent reporting practices across regions

Addressing these challenges requires harmonized regulations, professional education, and integration of digital health technologies[4].

Future Directions-

The future of pharmacovigilance lies in[6,7]

- Active surveillance using electronic health records
- Artificial intelligence–based signal detection
- Patient-reported outcomes
- Global collaboration for data sharing

These approaches can enhance early detection of safety concerns and improve regulatory decision-making.

Conclusion-

Pharmacovigilance is a cornerstone of patient safety in modern medicine[1]. Adverse drug reactions, though often preventable, continue to impose a substantial burden on healthcare systems[3]. A robust pharmacovigilance framework that encourages reporting, supports scientific assessment, and adapts to evolving therapeutic landscapes is essential[4]. Strengthening awareness among healthcare professionals and integrating advanced monitoring tools can

significantly reduce drug-related harm and promote safer pharmacotherapy[7,8].

Source of Support: Nil

Conflict of Interest: Nil

References-

1. World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: WHO; 2002.
2. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–9.
3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998;279(15):1200–5.
4. Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf. 2003;12(1):17–29.
5. Naranjo CA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.
6. Meyboom RH, Egberts AC, Edwards IR, Hekster YA. Principles of signal detection in pharmacovigilance. Drug Saf. 1997;16(6):355–65.
7. Rawlins MD. Pharmacovigilance: paradise lost, regained or postponed? J R Coll Physicians Lond. 1995;29(1):41–9.
8. Arora D, Bhushan I. Pharmacovigilance: an overview. Int J Pharm Sci Res. 2016;7(2):1–7